Table 1.

Indications for patients at risk of/with SARS-CoV-2 infection maintained at home

Patients on VKAs at risk of SARS-CoV-2 infection

If INR values are stable (i.e., time in therapeutic range > 60%), a prolongation of the INR control intervals may be considered (every 4–8 weeks)

The use of portable coagulometer devices with self-measurement of INR is encouraged

Switching from VKAs to DOACs must be considered

In the case of unstable INR values, switching from VKAs to DOACs is recommended

Patients on VKAs with mild COVID-19 maintained at home

The use of portable coagulometer devices with self-measurement of INR is encouraged

Switching from VKAs to DOACs must be considered, taking into account possible drug interactions

In the case of unstable INR values, switching from VKAs to DOACs is recommended

Patients not on oral anticoagulant therapy with asymptomatic SARS-CoV-2 infection

No thromboprophylaxis is indicated

Patients not on oral anticoagulant therapy with mild COVID-19

Thromboprophylaxis with LMWH is indicated if multiple risk factors for VTE are present and bleeding risk is low

COVID-19 coronavirus disease 2019, DOAC direct oral anticoagulant, INR international normalized ratio, LMWH low-molecular weight heparin, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, VKA vitamin K antagonist anticoagulant, VTE venous thromboembolism